China Shineway Pharmaceutical Group Limited

CSWYFOTCHealthcare● Active

$1.08

+$0.08(+7.57%)

Market Cap$815832000

P/E Ratio—

52W High$1.08

52W Low$0.9253

Avg Volume50.8

Open$1.00

Beta0.71

Free Cash Flow Financials Revenue

China Shineway Pharmaceutical Group Limited (CSWYF) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

CSWYF · free cash flow · updated Jun 9, 2026

Core FCF metrics

CSWYF · FCF · TTM · margin & CAGR

Free cash flow was $974.1M for FY2025 (fiscal year ending 2025-12-31), up 18.4% year-over-year The FCF margin was 31.1%. Five-year CAGR stands at +10.0%.

FY2025 Free Cash Flow$974.1M▲ +18.4% YoY

Trailing 12M (TTM)$1.64Btrailing 4 quarters sum

FCF Margin31.1%$974.1M ÷ revenue

3-Year CAGR-3.7%FY2022 → FY2025

5-Year CAGR+10.0%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

CSWYF · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$1.17B(198M)$974.1M▲ +18.4%31.1%

FY2024$963.1M(140M)$823.0M▼ 3.3%21.8%

FY2023$932.6M(144M)$851.5M▼ 22.0%2.7%

FY2022$1.11B(132M)$1.09B▲ +62.2%27.1%

FY2021$703.1M(92M)$672.7M▲ +11.2%21.2%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

CSWYF · P/FCF · FCF yield · FCF per share

China Shineway Pharmaceutical Group Limited (CSWYF) trades at a FCF yield of 19.55% and a price-to-free-cash-flow ratio of 0.5x. FCF per share stands at $2.17, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

19.55%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$2.17

TTM FCF ÷ Shares Outstanding

Price / FCF

x0.5

Share Price ÷ FCF per Share

EV / FCF (TTM)

x-1.4

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

CSWYF · cash flow statement · operating / investing / financing

For FY2025, China Shineway Pharmaceutical Group Limited generated $1.17B in operating cash flow and spent 198M in capital expenditures, yielding $974.1M in free cash flow.

Operating Activities

+$1.17B

Cash from core business operations

2025-12-31

Investing Activities

+$222.0M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$375.0M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($1.17B) − |CapEx| (198M) = FCF ($974.1M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

CSWYF vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

China Shineway Pharmaceutical Group LimitedYOU

CSWYF

$974.1M+18.4%31.1%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

China Shineway Pharmaceutical Group Limited (CSWYF) reported free cash flow of $974.1M for FY2025 (fiscal year ending 2025-12-31), up 18.4% year-over-year. The FCF margin was 31.1%.

Based on available data, China Shineway Pharmaceutical Group Limited has maintained positive free cash flow for at least 11 fiscal year(s). FCF peaked at $1.09B in FY2022. The 5-year CAGR stands at +10.0%.

China Shineway Pharmaceutical Group Limited's FCF yield is 19.55% and price-to-FCF ratio is 0.5x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

CSWYF free cash flow · 8 questions

China Shineway Pharmaceutical Group Limited free cash flow was $974.1M for FY2025, up 18.4% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $1.64B.

CSWYF free cash flowCSWYF FCFCSWYF FCF 2025CSWYF free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · China Shineway Pharmaceutical Group Limited · China Shineway Pharmaceutical Group Limited SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026